- Previous Close
2.1800 - Open
2.1300 - Bid 1.5800 x 200
- Ask 2.7900 x 200
- Day's Range
2.1300 - 2.2550 - 52 Week Range
1.6300 - 8.8500 - Volume
17,285 - Avg. Volume
46,626 - Market Cap (intraday)
10.04M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-4.0300 - Earnings Date Mar 25, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.00
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
www.biocardia.com16
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: BCDA
View More
Performance Overview: BCDA
Trailing total returns as of 2025-01-24, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCDA
View MoreValuation Measures
Market Cap
10.04M
Enterprise Value
6.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
60.84
Price/Book (mrq)
3.65
Enterprise Value/Revenue
86.68
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-115.93%
Return on Equity (ttm)
--
Revenue (ttm)
428k
Net Income Avi to Common (ttm)
-8.56M
Diluted EPS (ttm)
-4.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.42M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.85M
Research Analysis: BCDA
View MoreCompany Insights: BCDA
BCDA does not have Company Insights